EE197 Cost-Effectiveness of Monoclonal Antibodies (MABs) for Rheumatoid Arthritis (RA) in the United States

Abstract

In the last 2 decades, biologics have changed the treatment of RA. The 9 approved MABs on the market have shown improved outcomes. However, these agents created a massive economic burden among U.S. payers. Current methods of cost-containment relegate costs to patients while obstructing clinicians. Pharmacoeconomic analysis is commonly used by payers in decision-making. However, previous cost-effectiveness analyses (CEAs) present varying results with the use of Quality–Adjusted Life Years (QALYs). Therefore, there is a common necessity for a CEA using clinical endpoints in RA.